{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:59:47Z","timestamp":1772539187200,"version":"3.50.1"},"reference-count":96,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["Fund-UIDB\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDB\/00674\/2020"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["Fund-UIDP\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDP\/00674\/2020"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["Fund-UIDB\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDB\/00674\/2020"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["Fund-UIDP\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDP\/00674\/2020"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"ARDITI","award":["Fund-UIDB\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDB\/00674\/2020"]}]},{"name":"ARDITI","award":["Fund-UIDP\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDP\/00674\/2020"]}]},{"name":"ARDITI","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program to the Portuguese Mass Spectrometry Network through PROEQUIPRAM program","award":["Fund-UIDB\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDB\/00674\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program to the Portuguese Mass Spectrometry Network through PROEQUIPRAM program","award":["Fund-UIDP\/00674\/2020"],"award-info":[{"award-number":["Fund-UIDP\/00674\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program to the Portuguese Mass Spectrometry Network through PROEQUIPRAM program","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite the spectacular advances in molecular medicine, including genomics, proteomics, transcriptomics, lipidomics, and personalized medicine, supported by the discovery of the human genome, prostate cancer (PCa) remains the most frequent malignant tumor and a leading cause of oncological death in men. New methods for prognostic, diagnostic, and therapy evaluation are mainly based on the combination of imaging techniques with other methodologies, such as gene or protein profiling, aimed at improving PCa management and surveillance. However, the lack of highly specific and sensitive biomarkers for its early detection is a major hurdle to this goal. Apart from classical biomarkers, the study of endogenous volatile organic metabolites (VOMs) biosynthesized by different metabolic pathways and found in several biofluids is emerging as an innovative, efficient, accessible, and non-invasive approach to establish the volatilomic biosignature of PCa patients, unravelling potential biomarkers. This review provides a brief overview of the challenges of PCa screening methods and emergent biomarkers. We also focus on the potential of volatilomics for the establishment of PCa biomarkers from non-invasive matrices.<\/jats:p>","DOI":"10.3390\/cancers14163982","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T21:23:56Z","timestamp":1660771436000},"page":"3982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Volatilomics: An Emerging and Promising Avenue for the Detection of Potential Prostate Cancer Biomarkers"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-1175","authenticated-orcid":false,"given":"Cristina V.","family":"Berenguer","sequence":"first","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, NPRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"}]},{"given":"Ferdinando","family":"Pereira","sequence":"additional","affiliation":[{"name":"SESARAM\u2014Servi\u00e7o de Sa\u00fade da Regi\u00e3o Aut\u00f3noma da Madeira, EPERAM, Hospital Dr. N\u00e9lio Mendon\u00e7a, Avenida Lu\u00eds de Cam\u00f5es 6180, 9000-177 Funchal, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-5348","authenticated-orcid":false,"given":"Jorge A. M.","family":"Pereira","sequence":"additional","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, NPRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1965-3151","authenticated-orcid":false,"given":"Jos\u00e9 S.","family":"C\u00e2mara","sequence":"additional","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, NPRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"},{"name":"Departamento de Qu\u00edmica, Faculdade de Ci\u00eancias Exatas e Engenharia, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrurol.2015.182","article-title":"Intrapatient heterogeneity in prostate cancer","volume":"12","author":"Beltran","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dudka, I., Thysell, E., Lundquist, K., Antti, H., Iglesias-Gato, D., Flores-Morales, A., Bergh, A., Wikstr\u00f6m, P., and Gr\u00f6bner, G. (2020). Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06908-z"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-0-387-69080-3_17","article-title":"Prostate cancer susceptibility loci: Finding the genes","volume":"617","author":"Ostrander","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5653862","article-title":"Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy","volume":"2016","author":"Kgatle","year":"2016","journal-title":"Prostate Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Salciccia, S., Capriotti, A.L., Lagana, A., Fais, S., Logozzi, M., De Berardinis, E., Busetto, G.M., Di Pierro, G.B., Ricciuti, G.P., and Del Giudice, F. (2021). Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094367"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lee, S., Ku, J.Y., Kang, B.J., Kim, K.H., Ha, H.K., and Kim, S. (2021). A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma. Metabolites, 11.","DOI":"10.3390\/metabo11090591"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lima, A.R., Pinto, J., Amaro, F., Bastos, M.L., Carvalho, M., and Guedes de Pinho, P. (2021). Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites, 11.","DOI":"10.3390\/metabo11030181"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crad.2019.03.016","article-title":"Prostate biopsy: When and how to perform","volume":"74","author":"Das","year":"2019","journal-title":"Clin. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/s00259-013-2379-x","article-title":"Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry","volume":"40","author":"Spur","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-018-0683-0","article-title":"Development and Application of Liquid Biopsies in Metastatic Prostate Cancer","volume":"20","author":"Morrison","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.critrevonc.2017.11.007","article-title":"Biomarkers in prostate cancer\u2013Current clinical utility and future perspectives","volume":"120","author":"Kretschmer","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.08.010","article-title":"Long non-coding RNAs in prostate cancer: Functional roles and clinical implications","volume":"464","author":"Xu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Matuszczak, M., Schalken, J.A., and Salagierski, M. (2021). Prostate Cancer Liquid Biopsy Biomarkers\u2019 Clinical Utility in Diagnosis and Prognosis. Cancers, 13.","DOI":"10.3390\/cancers13133373"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41598-020-58836-4","article-title":"A predictive model for prostate cancer incorporating PSA molecular forms and age","volume":"10","author":"Oto","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","article-title":"Contemporary role of prostate cancer antigen 3 in the management of prostate cancer","volume":"60","author":"Auprich","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","article-title":"Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer","volume":"68","author":"Vickers","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_22","first-page":"149","article-title":"Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results","volume":"19","author":"Zappala","year":"2017","journal-title":"Rev. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41391-017-0008-7","article-title":"Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting","volume":"21","author":"White","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5001\/omj.2017.55","article-title":"Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience","volume":"32","author":"Saidi","year":"2017","journal-title":"Oman Med. J."},{"key":"ref_25","first-page":"E214","article-title":"Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis","volume":"14","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19870","article-title":"The clinical effectiveness and cost-effectiveness of the PROGENSA\u00ae prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: A systematic review and economic evaluation","volume":"19","author":"Nicholson","year":"2015","journal-title":"Health Technol. Assess."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score","volume":"70","author":"Hendriks","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_29","unstructured":"BridgeSpan (2020). Gene-Based Tests for Screening, Detection, and\/or Management of Prostate Cancer. Genetic Testing, Policy No. 17, BridgeSpan."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/pcan.2013.49","article-title":"A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy","volume":"17","author":"Ross","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/iju.13326","article-title":"Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice","volume":"24","author":"Narayan","year":"2017","journal-title":"Int. J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semcancer.2018.01.012","article-title":"New biomarkers for diagnosis and prognosis of localized prostate cancer","volume":"52","author":"Chistiakov","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_34","first-page":"300","article-title":"Modern biomarkers in prostate cancer diagnosis","volume":"73","author":"Porzycki","year":"2020","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_35","first-page":"135","article-title":"New biomarkers in prostate cancer","volume":"28","author":"Crawford","year":"2014","journal-title":"Oncology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/23808993.2017.1372687","article-title":"Tissue-based biomarkers in prostate cancer","volume":"2","author":"Clinton","year":"2017","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s11306-014-0659-5","article-title":"Biomarkers in renal cell carcinoma: A metabolomics approach","volume":"10","author":"Monteiro","year":"2014","journal-title":"Metabolomics"},{"key":"ref_38","first-page":"572","article-title":"Application of Metabolomics to Prostate Cancer","volume":"29","author":"Trock","year":"2011","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-019-0585-4","article-title":"Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine","volume":"121","author":"Lima","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rudaz, S. (2015). Identification and Data-Processing Methods in Metabolomics. Identification and Data Processing Methods in Metabolomics, Future Science Ltd.","DOI":"10.4155\/9781910420287"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tranon.2016.05.004","article-title":"Biomarker Discovery in Human Prostate Cancer: An Update in Metabolomics Studies","volume":"9","author":"Lima","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Silva, C., Perestrelo, R., Silva, P., Tom\u00e1s, H., and C\u00e2mara, J.S. (2019). Breast Cancer Metabolomics: From Analytical Platforms to Multivariate Data Analysis. A Review. Metabolites, 9.","DOI":"10.3390\/metabo9050102"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"bpz014","DOI":"10.1093\/biomethods\/bpz014","article-title":"Digging deeper into volatile organic compounds associated with cancer","volume":"4","author":"Janfaza","year":"2019","journal-title":"Biol. Methods Protoc."},{"key":"ref_44","first-page":"232","article-title":"Urinary metabolites for urological cancer detection: A review on the application of volatile organic compounds for cancers","volume":"7","author":"Gao","year":"2019","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/1078-0432.CCR-08-1059","article-title":"Clinical Applications of Metabolomics in Oncology: A Review","volume":"15","author":"Spratlin","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Aggarwal, P., Baker, J., Boyd, M.T., Coyle, S., Probert, C., and Chapman, E.A. (2020). Optimisation of Urine Sample Preparation for Headspace-Solid Phase Microextraction Gas Chromatography-Mass Spectrometry: Altering Sample pH, Sulphuric Acid Concentration and Phase Ratio. Metabolites, 10.","DOI":"10.3390\/metabo10120482"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.talanta.2017.08.064","article-title":"Gas chromatographic-mass spectrometric analysis of urinary volatile organic metabolites: Optimization of the HS-SPME procedure and sample storage conditions","volume":"176","author":"Safer","year":"2018","journal-title":"Talanta"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1038\/s41598-018-23847-9","article-title":"Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS","volume":"8","author":"Lima","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"C\u00e2mara, J.S., Perestrelo, R., Berenguer, C.V., Andrade, C.F.P., Gomes, T.M., Olayanju, B., Kabir, A., MR Rocha, C., Teixeira, J.A., and Pereira, J.A.M. (2022). Green Extraction Techniques as Advanced Sample Preparation Approaches in Biological, Food, and Environmental Matrices: A Review. Molecules, 27.","DOI":"10.3390\/molecules27092953"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1021\/ac00218a019","article-title":"Solid phase microextraction with thermal desorption using fused silica optical fibers","volume":"62","author":"Arthur","year":"1990","journal-title":"Anal. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.talanta.2011.12.041","article-title":"Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis","volume":"89","author":"Silva","year":"2012","journal-title":"Talanta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13113","DOI":"10.1038\/s41598-018-31380-y","article-title":"Exploring the potential of NTME\/GC-MS, in the establishment of urinary volatomic profiles. Lung cancer patients as a case study","volume":"8","author":"Pereira","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Capelli, L., Taverna, G., Bellini, A., Eusebio, L., Buffi, N., Lazzeri, M., Guazzoni, G., Bozzini, G., Seveso, M., and Mandressi, A. (2016). Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review. Sensors, 16.","DOI":"10.3390\/s16101708"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Filianoti, A., Costantini, M., Bove, A.M., Anceschi, U., Brassetti, A., Ferriero, M., Mastroianni, R., Misuraca, L., Tuderti, G., and Ciliberto, G. (2022). Volatilome Analysis in Prostate Cancer by Electronic Nose: A Pilot Monocentric Study. Cancers, 14.","DOI":"10.3390\/cancers14122927"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Tyagi, H., Daulton, E., Bannaga, A.S., Arasaradnam, R.P., and Covington, J.A. (2021). Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers. Biosensors, 11.","DOI":"10.21203\/rs.3.rs-223926\/v1"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bax, C., Taverna, G., Eusebio, L., Sironi, S., Grizzi, F., Guazzoni, G., and Capelli, L. (2018). Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review. Cancers, 10.","DOI":"10.3390\/cancers10040123"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40463-018-0288-5","article-title":"The volatilome\u2013investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC)","volume":"47","author":"Opitz","year":"2018","journal-title":"J. Otolaryngol.-Head Neck Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11306-017-1251-6","article-title":"Investigation of urinary volatomic alterations in head and neck cancer: A non-invasive approach towards diagnosis and prognosis","volume":"13","author":"Taware","year":"2017","journal-title":"Metabolomics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/bjc.2011.437","article-title":"Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry","volume":"105","author":"Silva","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3892\/br.2016.686","article-title":"Urinary volatile organic compounds as potential biomarkers for renal cell carcinoma","volume":"5","author":"Wang","year":"2016","journal-title":"Biomed. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"121604","DOI":"10.1016\/j.talanta.2020.121604","article-title":"Volatile organic compounds (VOCs) for the non-invasive detection of pancreatic cancer from urine","volume":"221","author":"Daulton","year":"2021","journal-title":"Talanta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2019.02.012","article-title":"Searching for selected VOCs in human breath samples as potential markers of lung cancer","volume":"135","author":"Rudnicka","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/09031936.00125411","article-title":"Breath analysis during one-lung ventilation in cancer patients","volume":"40","author":"Kischkel","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/bjs.10909","article-title":"Profile of exhaled-breath volatile organic compounds to diagnose pancreatic cancer","volume":"105","author":"Markar","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bjs.8942","article-title":"Exhaled volatile organic compounds identify patients with colorectal cancer","volume":"100","author":"Altomare","year":"2013","journal-title":"Br. J. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"560591","DOI":"10.3389\/fonc.2021.560591","article-title":"Advanced Diagnostic Technology of Volatile Organic Compounds Real Time analysis Analysis From Exhaled Breath of Gastric Cancer Patients Using Proton-Transfer-Reaction Time-of-Flight Mass Spectrometry","volume":"11","author":"Jung","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17725","DOI":"10.1038\/s41598-018-35854-x","article-title":"Volatilomic insight of head and neck cancer via the effects observed on saliva metabolites","volume":"8","author":"Taware","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.job.2020.05.002","article-title":"Identification of salivary volatile organic compounds as potential markers of the stomach and colorectal cancer: A pilot study","volume":"62","author":"Sarf","year":"2020","journal-title":"J. Oral Biosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1007\/s00216-018-1103-x","article-title":"Screening of salivary volatiles for putative breast cancer discrimination: An exploratory study involving geographically distant populations","volume":"410","author":"Cavaco","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_70","first-page":"4","article-title":"Establishment of the Saliva Volatomic Profile as an Exploratory and Non-invasive Strategy to Find Potential Breast Cancer Biomarkers","volume":"39","author":"Cavaco","year":"2014","journal-title":"Int. Labmate."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1007\/s00784-020-03754-y","article-title":"Evaluation of salivary VOC profile composition directed towards oral cancer and oral lesion assessment","volume":"25","author":"Monedeiro","year":"2021","journal-title":"Clin. Oral Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jb\/mvr090","article-title":"The scent of disease: Volatile organic compounds of the human body related to disease and disorder","volume":"150","author":"Shirasu","year":"2011","journal-title":"J. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/metabo5010003","article-title":"Breath analysis as a potential and non-invasive frontier in disease diagnosis: An overview","volume":"5","author":"Pereira","year":"2015","journal-title":"Metabolites"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/1520-667X(2000)12:11<577::AID-MCS30>3.0.CO;2-Q","article-title":"High capacity headspace sorptive extraction","volume":"12","author":"Tienpont","year":"2000","journal-title":"J. Microcolumn Sep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1039\/C9AN01478K","article-title":"Extending PTR-based breath analysis to real-time monitoring of reactive volatile organic compounds","volume":"144","author":"Pugliese","year":"2019","journal-title":"Analyst"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/02656736.2010.506470","article-title":"Proteomics, morpho-proteomics phosphoproteomics, saliva and breast cancer: An emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response","volume":"26","author":"Streckfus","year":"2010","journal-title":"Int. J. Hyperth."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"034001","DOI":"10.1088\/1752-7155\/8\/3\/034001","article-title":"The human volatilome: Volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva","volume":"8","author":"Amann","year":"2014","journal-title":"J. Breath Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/158786","article-title":"Salivary Diagnostics: A Brief Review","volume":"2014","author":"Malathi","year":"2014","journal-title":"ISRN Dent."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Pereira, J.A.M., Taware, R., Porto-Figueira, P., Rapole, S., and C\u00e2mara, J.S. (2020). The Salivary Volatome in Breast Cancer, Elsevier.","DOI":"10.1016\/B978-0-12-819178-1.00029-0"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lima, A.R., Pinto, J., Carvalho-Maia, C., Jer\u00f3nimo, C., Henrique, R., Bastos, M.d.L., Carvalho, M., and Guedes de Pinho, P. (2020). A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers. Cancers, 12.","DOI":"10.3390\/cancers12082017"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clinms.2020.10.004","article-title":"Analysis of urinary VOCs using mass spectrometric methods to diagnose cancer: A review","volume":"18","year":"2020","journal-title":"Clin. Mass Spectrom"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"a030452","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen Signaling in Prostate Cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11306-020-01691-1","article-title":"New findings on urinary prostate cancer metabolome through combined GC\u2013MS and 1H NMR analytical platforms","volume":"16","author":"Lima","year":"2020","journal-title":"Metabolomics"},{"key":"ref_85","first-page":"291","article-title":"The Roles of Cytochrome P450 Enzymes in Prostate Cancer Development and Treatment","volume":"32","author":"Chen","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s43440-020-00133-y","article-title":"Altered expression of cytochrome P450 enzymes involved in metabolism of androgens and vitamin D in the prostate as a risk factor for prostate cancer","volume":"72","author":"Maksymchuk","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Khalid, T., Aggio, R., White, P., De Lacy Costello, B., Persad, R., Al-Kateb, H., Jones, P., Probert, C.S., and Ratcliffe, N. (2015). Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143283"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpba.2014.12.026","article-title":"Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study","volume":"111","author":"Kordalewska","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clgc.2019.02.003","article-title":"Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer","volume":"17","author":"Gao","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_90","first-page":"243.e221","article-title":"Furan and p-xylene as candidate biomarkers for prostate cancer","volume":"36","author":"Iribar","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.bjc.6605810","article-title":"Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors","volume":"103","author":"Peng","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/iju.14912","article-title":"Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples","volume":"29","author":"Taverna","year":"2022","journal-title":"Int. J. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"20898","DOI":"10.1038\/s41598-021-00033-y","article-title":"Optimization of training and measurement protocol for eNose analysis of urine headspace aimed at prostate cancer diagnosis","volume":"11","author":"Capelli","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"017102","DOI":"10.1088\/1752-7163\/abc36b","article-title":"Differentiating cancer types using a urine test for volatile organic compounds","volume":"15","author":"Bannaga","year":"2020","journal-title":"J. Breath Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.euf.2018.11.006","article-title":"Exhaled-breath Testing for Prostate Cancer Based on Volatile Organic Compound Profiling Using an Electronic Nose Device (Aeonose\u2122): A Preliminary Report","volume":"6","author":"Waltman","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer","volume":"4","author":"Hogenhout","year":"2021","journal-title":"Eur. Urol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/3982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:11:24Z","timestamp":1760141484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/3982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":96,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14163982"],"URL":"https:\/\/doi.org\/10.3390\/cancers14163982","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}